Key points from article :
Centaura has begun developing the Human Artificial Chromosome (HAC), promising gene-delivery technology in geroscience.
Once developed, HACs promise to herald in a new era of genome engineering for human cells.
Capable of delivering up to 1000x more genetic information in a single treatment
Aging Profiles along with well-developed gene therapies effectively target multiple genes and pathways.
Centaura considers the bottom-up method to construct HAC, as de novo synthesis of chromosomes is far simpler and more reliable.
Complement other gene-therapy methods, such as CRISPR/Cas-9 technologies.
“HACs have the power to house and test multiple pathways that would otherwise take an incredible amount of labor and time with CRISPR/Cas,” - Alina Chan, Consultant at Centaura.
With recent advances in chromosome biology, gene sequencing and synthesis, Centaura is now on the brink of new generation HACs.
We can see the wide-reaching beneficial impact of HACs on studies and clinical treatments as soon as possible.
